Cargando…
MERS-CoV spike nanoparticles protect mice from MERS-CoV infection
The Middle East respiratory syndrome coronavirus (MERS-CoV) was first discovered in late 2012 and has gone on to cause over 1800 infections and 650 deaths. There are currently no approved therapeutics or vaccinations for MERS-CoV. The MERS-CoV spike (S) protein is responsible for receptor binding an...
Autores principales: | Coleman, Christopher M., Venkataraman, Thiagarajan, Liu, Ye V., Glenn, Gregory M., Smith, Gale E., Flyer, David C., Frieman, Matthew B. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier Ltd.
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5423355/ https://www.ncbi.nlm.nih.gov/pubmed/28237499 http://dx.doi.org/10.1016/j.vaccine.2017.02.012 |
Ejemplares similares
-
Growth and Quantification of MERS‐CoV Infection
por: Coleman, Christopher M., et al.
Publicado: (2015) -
Treating MERS-CoV during an outbreak
por: Coleman, Christopher M, et al.
Publicado: (2014) -
MERS-CoV
por: Müller, Marcel A
Publicado: (2014) -
Immunization of MERS-CoV-2-infected mice with a sublethal dose of MERS-CoV or VRP-MERS-S
por: Zheng, Jian, et al.
Publicado: (2023) -
MERS-CoV Infection of Alpaca in a Region Where MERS-CoV is Endemic
por: Reusken, Chantal B.E.M., et al.
Publicado: (2016)